On January 26, 2016, an affidavit or declaration regarding motion for authority to obtain debtor-in-possession financing was filed in the bankruptcy case of Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) and its affiliates.
The filing was assigned docket number 11 and is described on the court’s official docket as follows:
Affidavit/Declaration in Support of First Day Motion // Declaration of Peter S. Kaufman in Support of Debtor’s Motion for Entry of Interim and Final Orders Pursuant to Sections 105, 361, 362, 363(c), 363(m), 364(c)(1), 364(c)(2), 364(c)(3), 364(d)(1), 364(e), and 507 of the Bankruptcy Code and Bankruptcy Rules 2002, 4001, 6003, 6004, and 9014 (I) Authorizing the Debtor to Obtain Postpetition Financing, (II) Authorizing the Debtor to Use Cash Collateral and (III) Granting Adequate Protection to Prepetition Secured Parties Filed By Nuo Therapeutics, Inc. (Skomorucha Owens, Karen) (Entered: 01/26/2016)
Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on January 26, 2016. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 16-10192. The bankruptcy case is currently assigned to United States Bankruptcy Judge Mary Walrath. The law firm of Dentons US LLP is acting as lead bankruptcy counsel to Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) in the bankruptcy case.